Market Overview

3 Reasons Goldman Sachs Is Bullish On Kodiak Sciences

3 Reasons Goldman Sachs Is Bullish On Kodiak Sciences

Kodiak Sciences Inc’s (NASDAQ: KOD) main drug candidate, KSI-301, highlights the company’s focus on innovation in a dynamic treatment landscape, according to Goldman Sachs.

The Kodiak Sciences Analyst

Graig Suvannavejh initiated coverage of Kodiak Sciences with a Buy rating and a price target of $80.

The Kodiak Sciences Thesis

Based on a proprietary platform technology, Kodiak Sciences’ KSI-301 asset is focused on ophthalmology and is in a pivotal Phase 2/3 trial, with potential in multiple retinal diseases, Suvannavejh said in the note.

He cited three main reasons for the bullish rating:

  1. Large Commercial Opportunity With Concentrated End-Market: The lead indication for KSI-301 is wet age-related macular degeneration (AMD), which represents a large commercial market, estimated at around $11.5 billion in 2019 global sales for current branded competitors.
  2. May mManingfully Reduce Treatment Burden And Improve Outcomes: The current treatments typically require dosage at one- to two-month intervals, causing long wait times for patients and significantly impacting their quality of life. KSI-301 seeks to address this problem by “meaningfully improving the duration of effect for intravitreal injections.” So, KSI-301 could push the time between injections to five months or more.
  3. Faster Product Approval With Accelerated Clinical Development Timelines: Kodiak Sciences has an aggressive clinical development plan for its lead asset. This plan has been agreed to by the FDA. With the accelerated timelines, KSI-301 could begin generating revenue across multiple indications as early as 2023.

KOD Price Action

Shares of Kodiak Sciences were trading flat at time of publication Tuesday.

Latest Ratings for KOD

Jan 2021BMO CapitalDowngradesOutperformMarket Perform
Dec 2020BerenbergInitiates Coverage OnBuy
Dec 2020CitigroupInitiates Coverage OnNeutral

View More Analyst Ratings for KOD
View the Latest Analyst Ratings


Related Articles (KOD)

View Comments and Join the Discussion!

Posted-In: Goldman Sachs Graig SuvannavejhAnalyst Color Price Target Initiation Analyst Ratings

Latest Ratings

DEBMO CapitalMaintains400.0
PRITruist SecuritiesMaintains165.0
SHAKJP MorganMaintains70.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at